Abpro Holdings Seeks Reverse Stock Split Approval at Annual Meeting
Ticker: ABPWW · Form: DEF 14A · Filed: Sep 8, 2025 · CIK: 1893219
| Field | Detail |
|---|---|
| Company | Abpro Holdings, INC. (ABPWW) |
| Form Type | DEF 14A |
| Filed Date | Sep 8, 2025 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001, $160 million |
| Sentiment | mixed |
Sentiment: mixed
Topics: Reverse Stock Split, Annual Meeting, Corporate Governance, Biotechnology, Executive Leadership, Proxy Statement, Shareholder Vote
Related Tickers: ABPWW
TL;DR
**Abpro's reverse stock split is a desperate move to prop up share price; I'm bearish on ABPWW.**
AI Summary
Abpro Holdings, Inc. (ABPWW) is holding its Annual Meeting on September 18, 2025, to address three key proposals: re-electing one Class I director, ratifying Wolf & Company, P.C. as its independent registered public accounting firm for fiscal year 2025, and approving a one-for-ten reverse stock split. The company completed a Business Combination with Atlantic Coastal Acquisition Corp. II on November 13, 2024, resulting in ACAB changing its name to Abpro Holdings, Inc. The Board of Directors, composed of five members, has fixed September 2, 2025, as the record date, with 80,166,667 shares outstanding. Miles Suk became CEO in March 2025, succeeding Ian Chan. The proposed reverse stock split aims to consolidate shares, potentially to meet listing requirements or improve per-share metrics. The company's audit committee met twice in 2024 following the Business Combination.
Why It Matters
The proposed one-for-ten reverse stock split is a critical event for Abpro Holdings, Inc. investors, as it will significantly reduce the number of outstanding shares and increase the per-share price, potentially impacting liquidity and market perception. This move often signals a company's effort to meet exchange listing requirements or attract institutional investors, but it can also be viewed negatively by retail investors. For employees and customers, the financial stability implied by such a move could be reassuring, while the broader market will watch to see if this strategic maneuver improves Abpro's competitive standing in the biosciences industry, especially given its recent Business Combination and CEO change.
Risk Assessment
Risk Level: medium — The proposal for a one-for-ten reverse stock split (Proposal 3) indicates potential concerns about the company's stock price or Nasdaq listing compliance. While not explicitly stated as a delisting risk, reverse splits are often used to boost per-share price to meet minimum bid requirements, suggesting underlying stock performance issues. The recent change in CEO from Ian Chan to Miles Suk in March 2025, shortly after the November 2024 Business Combination, also introduces executive leadership transition risk.
Analyst Insight
Investors should carefully evaluate the implications of the one-for-ten reverse stock split, as it often signals underlying challenges. Consider the company's financial performance (from the 2024 10-K) and the strategic rationale beyond just meeting listing requirements before making any investment decisions.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Miles Suk | Chief Executive Officer and Chairman of the Board | |
| Ian Chan | former Chief Executive Officer | |
| Robert Markelewicz | Chief Medical Officer | |
| Christian Zapf | former Senior Vice President Corporate Development and former General Counsel |
Key Numbers
- 1-for-10 — Reverse Stock Split Ratio (Proposed ratio for the amendment to the Company's certificate of incorporation)
- September 18, 2025 — Annual Meeting Date (Date of the virtual Annual Meeting of Stockholders)
- September 2, 2025 — Record Date (Date for determining stockholders entitled to vote at the Annual Meeting)
- 80,166,667 — Shares Outstanding (Number of common shares outstanding on the record date)
- November 13, 2024 — Business Combination Completion Date (Date ACAB completed its combination with Abpro Corporation)
- March 2025 — CEO Transition Date (Miles Suk became CEO, succeeding Ian Chan)
- 2 — Audit Committee Meetings (Number of times the audit committee met in 2024 following the Business Combination)
- 5 — Total Directors (Current number of directors on the Board)
- 3 — Classes of Directors (Number of classes the Board is divided into with staggered terms)
- 2028 — Class I Director Term Expiration (Year Ian McDonald's term would expire if re-elected)
Key Players & Entities
- Abpro Holdings, Inc. (company) — Registrant and company holding the Annual Meeting
- Miles Suk (person) — Chief Executive Officer and Chairman of the Board since March 2025
- Ian Chan (person) — Former Chief Executive Officer until March 2025, current Director
- Wolf & Company, P.C. (company) — Independent registered public accounting firm for fiscal year 2025
- Anthony D. Eisenberg (person) — Chair of the Audit, Compensation, and Nominating and Corporate Governance Committees
- Ian McDonald (person) — Nominee for re-election as Class I director
- Atlantic Coastal Acquisition Corp. II (company) — Company that combined with Abpro Corporation in November 2024
- SEC (regulator) — U.S. Securities and Exchange Commission
- Nasdaq (regulator) — Stock exchange where Abpro Holdings, Inc. common stock is listed
- Robert Markelewicz (person) — Chief Medical Officer
FAQ
What is Abpro Holdings, Inc. proposing at its 2025 Annual Meeting?
Abpro Holdings, Inc. is proposing three key items at its Annual Meeting on September 18, 2025: the re-election of one Class I director, the ratification of Wolf & Company, P.C. as its independent registered public accounting firm for fiscal year 2025, and the approval of an amendment to its certificate of incorporation to effect a one-for-ten reverse stock split of its common stock.
When is Abpro Holdings, Inc.'s Annual Meeting and how can stockholders attend?
Abpro Holdings, Inc.'s Annual Meeting will be held virtually online on Thursday, September 18, 2025, at 10:00 a.m. Eastern Time. Stockholders can attend by visiting https://www.cstproxy.com/abpro/am2025 and entering the 12-digit control number received with their proxy card.
What is the record date for voting at Abpro Holdings, Inc.'s Annual Meeting?
The record date for determining holders of Abpro Holdings, Inc. common stock entitled to notice of, and to vote at, the Annual Meeting is the close of business on September 2, 2025. On this date, there were 80,166,667 shares of common stock outstanding.
Who is the current Chief Executive Officer of Abpro Holdings, Inc.?
J. Wook (Miles) Suk has served as the Chief Executive Officer of Abpro Holdings, Inc. since March 2025. He also serves as a Director and Chairman of the Board, having joined the Board following the Business Combination in November 2024.
Why is Abpro Holdings, Inc. proposing a reverse stock split?
Abpro Holdings, Inc. is proposing a one-for-ten reverse stock split to amend its certificate of incorporation. While the specific reasons are not detailed in this filing, reverse stock splits are typically implemented to increase the per-share price of a company's stock, often to meet minimum bid price requirements for stock exchange listings or to make the stock more attractive to institutional investors.
Who is nominated for re-election as a Class I director at Abpro Holdings, Inc.'s Annual Meeting?
Ian McDonald is nominated for re-election to the Board as a Class I director at Abpro Holdings, Inc.'s Annual Meeting. If elected, he will serve until the 2028 annual meeting of stockholders.
Who is Abpro Holdings, Inc.'s independent registered public accounting firm for 2025?
Wolf & Company, P.C. has been appointed as Abpro Holdings, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025. Stockholders are asked to ratify this appointment at the Annual Meeting.
What was the significant corporate event for Abpro Holdings, Inc. in November 2024?
On November 13, 2024, Atlantic Coastal Acquisition Corp. II (ACAB) completed a Business Combination with Abpro Corporation. Following this, ACAB changed its name to Abpro Holdings, Inc., and Abpro Corporation became a wholly owned subsidiary.
How many independent directors are on Abpro Holdings, Inc.'s Board?
Abpro Holdings, Inc.'s Board consists of a majority of independent directors. Specifically, out of five directors, Mr. Eisenberg, Mr. McDonald, and Mr. Lee qualify as independent directors as defined under Nasdaq listing rules and SEC rules, while Mr. Chan and Mr. Suk do not.
What are the primary responsibilities of Abpro Holdings, Inc.'s Audit Committee?
The primary purpose of Abpro Holdings, Inc.'s Audit Committee is to discharge the Board's responsibilities regarding the company's accounting, financial, and other reporting and internal control practices. It also oversees the independent registered accounting firm, and its members, including chair Anthony D. Eisenberg, are all independent directors.
Industry Context
Abpro Holdings, Inc. operates in the biotechnology or pharmaceutical sector, focusing on developing novel therapeutics. This industry is characterized by high R&D costs, long development cycles, significant regulatory hurdles from bodies like the FDA, and intense competition from established pharmaceutical giants and emerging biotech firms. Success often hinges on innovation, clinical trial outcomes, and securing funding.
Regulatory Implications
The company faces standard regulatory scrutiny common in the biotech industry, particularly concerning clinical trial conduct and drug approval processes. The proposed reverse stock split may be an attempt to comply with stock exchange listing requirements, which often have minimum per-share price thresholds, thus avoiding delisting risks.
What Investors Should Do
- Vote on Proposal 1: Re-election of Class I Director
- Vote on Proposal 2: Ratification of Independent Auditor
- Vote on Proposal 3: Approval of 1-for-10 Reverse Stock Split
- Review Executive Compensation
Key Dates
- 2025-09-18: Annual Meeting of Stockholders — To vote on re-electing a director, ratifying the independent auditor, and approving a 1-for-10 reverse stock split.
- 2025-09-02: Record Date — Determines which stockholders are entitled to vote at the Annual Meeting.
- 2024-11-13: Business Combination Completion Date — The date Atlantic Coastal Acquisition Corp. II completed its combination with Abpro Corporation, leading to the company's current structure.
- 2025-03: CEO Transition — Miles Suk became CEO, succeeding Ian Chan, indicating a leadership change.
- 2024-12-31: Fiscal Year End — The period for which the independent registered public accounting firm is being ratified and for which compensation tables are provided.
Glossary
- DEF 14A
- A proxy statement filed with the SEC by publicly traded companies to solicit shareholder votes for annual meetings. (This document contains the information being analyzed, including proposals for the annual meeting and executive compensation details.)
- Business Combination
- A merger or acquisition transaction where two or more companies combine into a single entity. (Abpro Holdings, Inc. was formed through a business combination with Atlantic Coastal Acquisition Corp. II on November 13, 2024.)
- Reverse Stock Split
- A corporate action to reduce the number of outstanding shares of a company's stock by consolidating them. (Abpro Holdings, Inc. is proposing a 1-for-10 reverse stock split to potentially meet listing requirements or improve per-share metrics.)
- Independent Registered Public Accounting Firm
- An external audit firm hired to provide an independent opinion on a company's financial statements. (Wolf & Company, P.C. is proposed to be ratified as Abpro's auditor for fiscal year 2025.)
- Record Date
- A specific date set by a company to determine which shareholders are eligible to receive dividends, vote on corporate matters, or receive other distributions. (September 2, 2025, is the record date for determining stockholders entitled to vote at the September 18, 2025, Annual Meeting.)
- Named Executive Officers (NEOs)
- The top executive officers of a company whose compensation is disclosed in SEC filings. (The proxy statement identifies Miles Suk, Ian Chan, Robert Markelewicz, and Christian Zapf as the company's NEOs for the purpose of this filing.)
Year-Over-Year Comparison
This filing follows a significant Business Combination completed in November 2024, which fundamentally changed the company's structure and reporting. Therefore, direct year-over-year comparisons of key financial metrics like revenue, net income, or margins from prior filings are not directly applicable to the current entity, Abpro Holdings, Inc. New risks and governance considerations may have emerged post-combination, and the focus is on the upcoming annual meeting proposals and recent leadership changes.
Filing Stats: 4,574 words · 18 min read · ~15 pages · Grade level 13.3 · Accepted 2025-09-08 16:18:03
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share ("common stock"), issued and
- $160 million — M&A and capital markets resulting in a $160 million sale within one year. Previously, he wo
Filing Documents
- ea0255107-02.htm (DEF 14A) — 1038KB
- tproxy_001.jpg (GRAPHIC) — 1224KB
- tproxy_002.jpg (GRAPHIC) — 1282KB
- 0001213900-25-085529.txt ( ) — 7328KB
- abp-20250908.xsd (EX-101.SCH) — 9KB
- abp-20250908_def.xml (EX-101.DEF) — 2KB
- abp-20250908_lab.xml (EX-101.LAB) — 33KB
- ea0255107-02_htm.xml (XML) — 13KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 26 Explanation of Certain Calculations in the Table of Certain Beneficial Owners 26 CERTAIN RELATIONSHIPS AND RELATED PERSONS TRANSACTIONS 27 Pre-Closing Related Party Transactions 27 Indemnification of Our Directors and Officers 31 Post-Closing Related Party Transactions 32 Policies for Approval of Related Party Transactions 32 EXECUTIVE OFFICERS 34
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 35 2024 Summary Compensation Table 36
Executive Compensation Arrangements
Executive Compensation Arrangements 37 Outstanding Equity Awards as of December 31, 2024 38 QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING 39 OTHER MATTERS 46 CONTACT FOR QUESTIONS AND ASSISTANCE WITH VOTING 46 i Table of Contents ABPRO HOLDINGS, INC. 100 Summit Drive Burlington, MA 01803 1-800-396-5890 PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS INTRODUCTION 2025 Annual Meeting of Stockholders This proxy statement and associated proxy card are furnished in connection with the solicitation of proxies to be voted at the 2025 Annual Meeting of Stockholders (the "Annual Meeting") of Abpro Holdings, Inc. ("we," "us," the "Company" or "New Abpro"), which will be held on Thursday, September 18, 2025, at 10:00 a.m. Eastern Time virtually via the Internet at https://www.cstproxy.com/abpro/am2025 . You will need to enter the 12 -digit control number received with your proxy card to enter the Annual Meeting via the online web portal. By visiting this website, you may attend the Annual Meeting virtually online, vote your shares electronically and submit your questions to management during the Annual Meeting. This proxy statement and our Annual Report on Form 10 -K for the year ended December 31, 2024 (the "Annual Report") are available to stockholders at https://www.cstproxy.com/abpro/am2025 . The proxy statement for the Annual Meeting (the "proxy statement") contains important information about the Annual Meeting and each of the proposals. Whether or not you plan to attend the Annual Meeting, the Company urges you to read this material carefully and vote your shares. This proxy statement for the Annual Meeting is dated September 8, 2025 and is being distributed or made available to stockholders on or about that date. Proposals to be Voted on at the Annual Meeting The following matters are scheduled to be voted on at the Annual Meeting: Proposal 1: To re -elect one Class I director nominated by our Board and named in this proxy